Your email has been successfully added to our mailing list.

×
0 -0.00553505535055339 0 0 -0.00553505535055339 -0.00738007380073801 0.0129151291512916 0.0129151291512916
Stock impact report

ImmunityBio: Anktiva Approval Opens Up A World Of Possibilities, Risks And Potential Gains [Seeking Alpha]

ImmunityBio, Inc. (IBRX) 
Company Research Source: Seeking Alpha
Anktiva received Breakthrough Therapy Designation and approval from the FDA based on its safety and efficacy outcomes, which appear to have "best-in-class" potential. ImmunityBio's founder, Dr. Patrick Soon-Shiong, owns the majority of the company and plans to launch five new drugs between 2021 and 2025. The entrepreneur has been remarkably successful in pharma. Investment Overview ImmunityBio ( NASDAQ: IBRX ), the San Diego-based biotech led by well-known biotech entrepreneur Dr. Patrick Soon-Shiong, was celebrating today as the company scored its first US drug approval, for its lead drug candidate Anktiva. According to a press release issued Show less Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
IBRX alerts

from News Quantified
Opt-in for
IBRX alerts

from News Quantified